DAVENPORT & Co LLC Has $2.17 Million Stock Position in Zoetis Inc. $ZTS

DAVENPORT & Co LLC cut its position in Zoetis Inc. (NYSE:ZTS) by 51.9% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 17,244 shares of the company’s stock after selling 18,638 shares during the quarter. DAVENPORT & Co LLC’s holdings in Zoetis were worth $2,171,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in ZTS. Norges Bank bought a new position in shares of Zoetis in the second quarter valued at approximately $809,491,000. Diamond Hill Capital Management Inc. bought a new stake in Zoetis during the 3rd quarter worth approximately $394,010,000. Nordea Investment Management AB increased its holdings in Zoetis by 79.2% during the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock valued at $622,222,000 after purchasing an additional 2,179,578 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in Zoetis by 83.4% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,697,827 shares of the company’s stock valued at $394,746,000 after purchasing an additional 1,227,085 shares in the last quarter. Finally, Corient Private Wealth LLC raised its position in Zoetis by 85.9% in the 2nd quarter. Corient Private Wealth LLC now owns 2,578,593 shares of the company’s stock valued at $400,619,000 after purchasing an additional 1,191,840 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ZTS. BTIG Research restated a “buy” rating and set a $160.00 target price on shares of Zoetis in a report on Thursday, February 26th. Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Bank of America increased their price objective on shares of Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a report on Friday, February 13th. HSBC set a $140.00 price objective on shares of Zoetis in a research report on Wednesday, December 10th. Finally, Piper Sandler reiterated a “neutral” rating and set a $135.00 target price (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. Six analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Zoetis has a consensus rating of “Hold” and an average target price of $152.91.

Zoetis Price Performance

Zoetis stock opened at $113.48 on Friday. The business’s 50-day simple moving average is $123.39 and its 200 day simple moving average is $129.17. The stock has a market cap of $47.90 billion, a price-to-earnings ratio of 18.85, a P/E/G ratio of 1.73 and a beta of 0.95. Zoetis Inc. has a 12-month low of $113.29 and a 12-month high of $172.23. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm had revenue of $2.39 billion during the quarter, compared to analysts’ expectations of $2.36 billion. During the same period in the previous year, the business posted $1.40 EPS. The company’s quarterly revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be paid a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s payout ratio is 35.22%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.